年龄和性别影响他汀治疗对全身代谢功能障碍期间肝脏衰老的转录组反应
研究分析368名Duke MASLD生物库成人肝脏转录组和临床数据,发现他汀使用者(尤其老年人)血清ALT、AST和LDL胆固醇更低,转录组显示衰老相关通路受抑制而铁死亡通路激活,经倾向评分匹配和独立肥胖队列验证。
要点
- 他汀使用与衰老相关通路抑制和铁死亡通路激活相关
- 老年他汀使用者ALT、AST和LDL胆固醇水平更低
- 他汀可能作为衰老细胞清除剂抑制MASLD中的生物学衰老
核心结论
- 他汀使用者的肝脏衰老相关通路受抑制而铁死亡通路被诱导,提示他汀可能通过衰老细胞清除作用抑制MASLD中的生物学衰老。
研究设计与样本
- 分析368名Duke MASLD生物库成人的肝脏转录组和匹配临床数据,关注年龄依赖反应及衰老与铁死亡的相互作用。
主要发现
- 他汀使用者的血清ALT、AST和LDL胆固醇水平较低,尤其在老年人中。
- 他汀使用与衰老相关通路抑制及铁死亡相关通路激活强烈相关,经倾向评分匹配控制临床混杂因素后持续存在,并在独立肥胖队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Older age increases susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD), but whether it impacts response to therapies, and how the therapies impact regulators of biological aging, are poorly understood. Statins inhibit the mevalonate pathway to block cholesterol biosynthesis and are widely used in MASLD patients to reduce cardiovascular disease. Whether statins prevent progression to cirrhosis is under investigation. However, the molecular effects of statins in human liver, particularly in the context of aging, remain poorly defined. APPROACH AND RESULTS: We analyzed liver transcriptomes and matched clinical data from 368 adults enrolled in the Duke MASLD Biorepository with a focus on age-dependent responses and the interplay between senescence and ferroptosis, a regulated death process that is constrained by the mevalonate pathway. Serum ALT, AST, and LDL cholesterol levels were lower in statin users of both sexes, particularly among older individuals. Transcriptome analyses revealed that statin use is strongly associated with suppression of senescence-related pathways. Statin use is also associated with increased activation of pathways linked to ferroptosis. Both responses persisted after propensity score matching to control for clinical confounders and were validated in an independent obese cohort. CONCLUSIONS: Age-dependent transcriptional remodeling in the liver differs in statin users and non-users. Pathways involved in senescence are suppressed while those that promote ferroptosis are induced in statin users. These results suggest that statins may suppress biological aging in MASLD by acting as senolytics and highlight the complex, context-specific roles of senescence in liver adaptation and remodeling.
引用
- Umbaugh DS, Wang L, Du K, et al. Age and sex influence transcriptomic responses to statin therapy that control liver aging during systemic metabolic dysfunction. Hepatology. 2026. PMID: 41627886. doi:10.1097/HEP.0000000000001704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。